⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13736300 | 0.96 | — | — | |
| SCHEMBL656738 | 0.96 | LMNA (0.52) | — | |
| Hydrochloric Acid SCHEMBL2554902 | 0.93 | LMNA (0.55) | — | |
| SCHEMBL6130386 | 0.93 | LMNA (0.50) | — | |
| SCHEMBL24243950 | 0.80 | LMNA (0.41) | — | |
| SCHEMBL18543255 | 0.80 | LMNA (0.41) | — | |
| SCHEMBL5607957 | 0.80 | DPP4 (0.37) | — | |
| SCHEMBL18543254 | 0.80 | LMNA (0.41) | — | |
| SCHEMBL3332166 | 0.80 | LMNA (0.41) | — | |
| SCHEMBL5608216 | 0.80 | DPP4 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| CN-115835909-A | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4146345-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11339162-B1 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2021226206-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021127499-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3193855-B1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |